Privia Health Group, Inc.

PRVA

Nasdaq; healthcare; SIC 8000, Services-Health Services; CIK 0001759655

None

No letter

6 of 14 inputs computable; 7 are required, with a score in every sleeve

Scoreboard	
Reliability	0.91 AUC filers with $591M to $2.67B assets; 95% interval 0.88 to 0.94; 160 events, 2020 to 2025
Peer failure rate	1.01% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	$591M to $2.67B assets total assets $1.4B
Standard universe	inside revenue above $1M and assets above $10M
Warnings	thin data not computable: distress, fortress balance sheet
Inputs computable	6 of 14
Graded from	filings received through Feb 27, 2026 256 days before the rescan; latest periodic filing 10-Q received Nov 5, 2026
Last close	$24.55 2026-11-09; market equity $3.1B; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Feb 27, 2026

Privia Health Group, Inc. ("Privia Health", "we", "our", or the "Company") is a technology-driven, national physician-enablement company that collaborates with physician practices, health plans, and health systems to achieve the quadruple aim of better outcomes, lower costs, improved patient experience, and happier and more engaged providers.

The fourteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 38.0						
Gross profitability	not computable	32.3%				
one or more required annual facts are missing						
Return on invested capital	not computable	9.3%				
one or more required annual facts are missing						
Accruals ratio	(11.2%)	(6.6%)		38.0	800	2025-12-31

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Gross margin stability, five years	not computable	2.8 pts				
five annual gross margins are required; found 0						
Solvency, sleeve percentile 52.0						
Twelve-month failure probability	not computable	0.08%				
latest liabilities, cash plus short-term investments, book equity, and shares are required						
Altman Z double-prime	2.77	(0.35)		26.1	745	2025-12-31
Net debt to EBITDA	not computable	1.82x				
one or more required annual facts are missing						
Interest coverage	not computable	(4.51x)				
latest aligned inputs end 2022-12-31; latest annual assets end 2025-12-31						
Current ratio	1.60x	2.95x		77.9	826	2025-12-31
Growth and financing, sleeve percentile 31.4						
Revenue growth, three-year compound	16.1%	10.1%		38.0	411	2025-12-31
Free cash flow growth, three-year compound	not computable	11.0%				
four consecutive annual FCF observations are required; found 3						
Reinvestment rate	not computable	37.1%				
latest aligned inputs end 2023-12-31; latest annual assets end 2025-12-31						
Asset growth, three years	20.0%	2.2%		21.4	694	2025-12-31
Net share issuance, one year	2.6%	2.5%		34.9	629	2026-02-20

Warnings

1 of 7 checks triggered; none of them enters the letter

Check	Measured
Thin data	6 of 14 grade factors are computable; minimum is 7

What the price implies

at the 2026-11-09 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	(19.0%)	(1.9%)	38
Distance from 52-week high	(12.7%)	(27.5%)	68
EBIT to enterprise value	not computable	(1.5%)	
Free cash flow yield	2.6%	(1.0%)	69
Book value to price	0.26	0.27	48
Sales to price	0.68	0.29	75
Composite equity issuance, five years	not computable	20.8%	
Relative strength against the sector, log excess return	(0.38)	(0.19)	38

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	pass
Operating cash flow above zero	pass
Return on assets improved	pass
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	fail
No new shares issued	fail
Gross margin improved	fail
Asset turnover improved	pass
Cash, filings, liquidity	

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Cash and equivalents	$446.3M
Operating cash flow, four quarters	$108.1M
Months of runway	not finite
Days since last periodic filing	5 (10-Q received Nov 5, 2026)
Median daily dollar volume, 63 sessions	$23.0M

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	net income	us-gaap:NetIncomeLoss	$22.9M	2025-12-31	2026-02-27	10-K	26-000010
2	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$163.4M	2025-12-31	2026-02-27	10-K	26-000010
3	assets	us-gaap:Assets	$1.4B	2025-12-31	2026-02-27	10-K	26-000010
4	assets	us-gaap:Assets	$1.1B	2024-12-31	2026-02-27	10-K	26-000010
5	current assets	us-gaap:AssetsCurrent	$911.0M	2025-12-31	2026-02-27	10-K	26-000010
6	current liabilities	us-gaap:LiabilitiesCurrent	$568.5M	2025-12-31	2026-02-27	10-K	26-000010
7	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-$156.3M	2025-12-31	2026-02-27	10-K	26-000010
8	operating income	us-gaap:OperatingIncomeLoss	$34.2M	2025-12-31	2026-02-27	10-K	26-000010
9	book equity	us-gaap:StockholdersEquity	$737.2M	2025-12-31	2026-02-27	10-K	26-000010
10	liabilities	us-gaap:Liabilities	$578.4M	2025-12-31	2026-02-27	10-K	26-000010
11	operating income	us-gaap:OperatingIncomeLoss	-$19.1M	2022-12-31	2025-02-27	10-K	25-000018
12	interest expense	us-gaap:InterestExpense	$500,000	2022-12-31	2023-03-01	10-K	23-000026
13	revenue	us-gaap:RevenueFromContractWithCustomerIncludingAs...	$2.1B	2025-12-31	2026-02-27	10-K	26-000010
14	revenue	us-gaap:RevenueFromContractWithCustomerIncludingAs...	$1.7B	2024-12-31	2026-02-27	10-K	26-000010
15	revenue	us-gaap:RevenueFromContractWithCustomerIncludingAs...	$1.7B	2023-12-31	2026-02-27	10-K	26-000010
16	revenue	us-gaap:RevenueFromContractWithCustomerIncludingAs...	$1.4B	2022-12-31	2025-02-27	10-K	25-000018
17	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$113,000	2023-12-31	2024-02-27	10-K	24-000022
18	depreciation amortization	us-gaap:DepreciationDepletionAndAmortization	$6.5M	2023-12-31	2026-02-27	10-K	26-000010
19	operating income	us-gaap:OperatingIncomeLoss	$20.6M	2023-12-31	2026-02-27	10-K	26-000010
20	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeInc...	$29.0M	2023-12-31	2026-02-27	10-K	26-000010
21	income tax	us-gaap:IncomeTaxExpenseBenefit	$8.0M	2023-12-31	2026-02-27	10-K	26-000010
22	current assets	us-gaap:AssetsCurrent	$700.8M	2023-12-31	2025-02-27	10-K	25-000018
23	current liabilities	us-gaap:LiabilitiesCurrent	$387.0M	2023-12-31	2025-02-27	10-K	25-000018
24	current assets	us-gaap:AssetsCurrent	$552.0M	2022-12-31	2024-02-27	10-K	24-000022
25	current liabilities	us-gaap:LiabilitiesCurrent	$264.3M	2022-12-31	2024-02-27	10-K	24-000022
26	assets	us-gaap:Assets	$999.9M	2023-12-31	2025-02-27	10-K	25-000018
27	assets	us-gaap:Assets	$792.8M	2022-12-31	2024-02-27	10-K	24-000022
28	shares outstanding	dei:EntityCommonStockSharesOutstanding	123,688,289	2026-02-20	2026-02-27	10-K	26-000010
29	shares outstanding	dei:EntityCommonStockSharesOutstanding	120,513,183	2025-02-21	2025-02-27	10-K	25-000018

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.